Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682498 · ClinicalTrials.gov registry record · Phase 4
Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj
A Phase 4 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT02682498 is a Phase 4 study that has completed, run by University of California, Irvine. The registered enrollment target is 38 participants.
The verdict
NCT02682498, a Phase 4 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after surgery will decrease opioid consumption and adverse events in opioid-tolerant patients presenting for total knee arthroplasty. The research hypothesis is that the Exparel (study) group will use less opioid in the first 48 hours post-operatively than the control group.
Interventions
- DRUG (Bupivacaine Liposome Injectable Suspension)
- DRUG Standard Preparation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682498
The ClinicalTrials.gov registry entry for NCT02682498 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which (Bupivacaine Liposome Injectable Suspension) is the first listed.
NCT02682498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02682498 about?
NCT02682498 is a clinical study titled "Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj". This study seeks to determine whether a new sustained-release local anesthetic solution (Exparel - Liposomal Bupivacaine) injected into the soft tissues around the joint after surgery will decrease opioid consumption and adverse events in opioid-tolerant patients presenting for total knee arthroplas...
What is the current status of trial NCT02682498?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2013-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02682498?
The interventions under investigation include: (Bupivacaine Liposome Injectable Suspension) (DRUG), Standard Preparation (DRUG).
Who is sponsoring clinical trial NCT02682498?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.